Table 1. Characteristics of meta-analyses included.

Authors	Kind of MA	Period	Stent and generation	Nb. Trials included	Nb. patients	Characteristics of patients	AMSTAR score
[8]	Network MA	Up to April 2012	BMS, DES-1, DES-2	42 RCT	10,714 patients	Diabetic patients with coronary-artery disease and primary PCI	10/11
[9]	Network MA	Up to March 2012	BMS, DES-1, DES-2	76 RCT	57,138 patients	Patients with coronary-artery disease and primary PCI	9.5/11
[10]	Network MA	Up to March 2013	BMS, DES-1, DES-2	28 RCT	14,740 patients	Patients with STEMI	9.5/11
[6]	MA	Up to March 2012	BMS, DES-1, DES-2	6 RCT	4,393 patients	Patients with coronary-artery disease and large vessels (> = 3 mm)	10/11
[4]	Network MA	2002 to 2011	BMS, DES-1, DES-2	49 RCT	50,844 patients	Patients with coronary-artery disease	10/11
[11]	Network MA	Up to 2012	BMS, DES-1, DES-2	22 RCT	12,453 patients	Patients with STEMI and primary PCI	10/11
[12]	Network MA	Up to 2013	BMS, DES-1, DES-2, BS	89 RCT	85,490 patients	Patients with coronary-artery disease	10.5/11
[13]	Network MA	Up to 2014	BMS, DES-1, DES-2, BS	51 RCT	52,158 patients	Patients with coronary-artery disease	10.5/11
[14]	MA with patient-level data	Up to December 2013	BMS, EES	5 RCT	4,896 patients	Patients with coronary-artery disease	9/11
[15]	MA	Up to July 2013	BMS, DES-1, DES-2	10 RCT	7,592 patients	Patients with STEMI	10/11

Notes: MA: Meta-analysis, BMS: Bare-metal stent, DES: Drug-eluting stent (generation 1 or 2), BS: Bioabsorbable stent, EES: Everolimus-eluting stent, RCT: randomized controlled trial, PCI: Percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infraction.